NTINeurotech
About Neurotech
Neurotech International (ASX:NTI) is a biopharmaceutical company focused on the development and commercialisation of neurological solutions that improve quality of life. The company's lead drug candidate, NTI164, is currently in Phase II clinical trials for the treatment of moderate autism spectrum disorder in children. NTI is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. NTI's operations are centred around its two key projects: the NTI164 clinical trials and the commercialisation of Mente.
What is NTI known for?
Snapshot
Public AU
Ownership
2016
Year founded
10
Employees
Nedlands, Western Australia
Head office
1 of 391
AU Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Produtos e/ou serviços de Neurotech
- NTI164: a potent blend of CBDA and assorted minor cannabinoids, including less than 0.3% THC, offers a distinct mechanism from CBD, actively targeting inflammatory pathways and inhibiting cytokine activity.
- Mente: Mente uses personalised audio feedback and earphones to gently guide the brain into a more relaxed state. Based on autism research and a successful clinical trial, Mente is a soft, easy to use and portable headband that was developed to help those on the autism spectrum improve their ability to relax.
equipe executiva do Neurotech
- Dr. Anthony Filippis M.B.A., Ph.D.MD, CEO & Director
- Mr. Gerald QuigleyDirector of Public Relations & Director
- Dr. Emanuela RussoChief Scientific Officer & Member of Scientific Advisory Board
- Associate Prof. Carolyn EllawayChief Medical Officer
- Dr. Bonni Goldstein M.D.Chief Medical Advisor for USA
- Mr. Peter James Lawrence Griffiths B.Sc.Chief Executive Officer of AAT Research Ltd
- Ms. Alessandra Marie GauvinCompany Secretary